StewartA.SharpMD

Oncology • Bismarck, ND

Physician

Join to view full profile

Dr. Sharp is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sharp's full profile

Already have an account?

Office
401 N 9th St
Lbby
Bismarck, ND 58501
Phone+1 701-712-4500

Fax+1 701-712-4098

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1984 - 1986
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1981 - 1984
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1981

Certifications & Licensure

SC State Medical License 2016 - 2023
ND State Medical License 2020 - 2020
TX State Medical License 2007 - 2017
VA State Medical License 1987 - 2008
IA State Medical License 1981 - 1987
IL State Medical License 1982 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013-2014

Clinical Trials

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Start of enrollment: 2010 Jun 22
Completed
Phase 2
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

403 citations
Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practi...
D. Andrew Loblaw, Katherine S. Virgo, Robert Nam, Mark R. Somerfield, Edgar Ben-Josef
Journal of Clinical Oncology. 2007-04-20
134 citations
American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer
D. Andrew Loblaw, David S. Mendelson, James A. Talcott, Katherine S. Virgo, Mark R. Somerfield
Journal of Clinical Oncology. 2004-07-15
206 citations
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
Eric P. Winer, Donald A. Berry, Susan Woolf, David B. Duggan, Alice B. Kornblith
Journal of Clinical Oncology. 2004-06-01

Professional Memberships

American College of Physicians - ACP
Member